R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
Events Partner Content Welcome to 1st Rare & Genetic Neurodegenerative Drug Dev... Developing R&G neurodegenerative therapies
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
